Search Results - "Guckert, Mary E"

Dabrafenib in BRAF -mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial by Hauschild, Axel, Prof, Grob, Jean-Jacques, Prof, Demidov, Lev V, Prof, Jouary, Thomas, MD, Gutzmer, Ralf, MD, Millward, Michael, MD, Rutkowski, Piotr, PhD, Blank, Christian U, PhD, Miller, Wilson H, PhD, Kaempgen, Eckhart, PhD, Martín-Algarra, Salvador, PhD, Karaszewska, Boguslawa, MD, Mauch, Cornelia, Prof, Chiarion-Sileni, Vanna, MD, Martin, Anne-Marie, PhD, Swann, Suzanne, PhD, Haney, Patricia, BSN, Mirakhur, Beloo, PhD, Guckert, Mary E, MSN, Goodman, Vicki, MD, Chapman, Paul B, MD

“…Summary Background Dabrafenib, an inhibitor of mutated BRAF, has clinical activity with a manageable safety profile in studies of phase 1 and 2 in patients…”
Get full text

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma by Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C., Lassen, Ulrik, Laubach, Jacob P., Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A. Kate, Guckert, Mary E., de Boer, Carla, Khokhar, Nushmia Z., Yeh, Howard, Clemens, Pamela L., Ahmadi, Tahamtan, Lokhorst, Henk M., Richardson, Paul G.

“…Daratumumab, a human CD38 immunoglobulin G1 kappa (IgG1κ) monoclonal antibody, has activity as monotherapy in multiple myeloma (MM). This phase 1/2 study…”
Get full text

Preclinical characterization of human Kallikrein 2 (hK2) as a novel target for the treatment of prostate cancer by Shen, Fei, Kelly, William Kevin, Pandit-Taskar, Neeta, McDevitt, Theresa, Smith, Ryan, Menard, Krista, Packman, Kathryn, Chaudhary, Ruchi, Rupnow, Brent, Yu, Margaret K., Guckert, Mary E., Tian, Shaozhou Ken, Chu, Gerald, Xie, Hong, Patricia, Daniel, Max, Steven I, Morris, Michael J.

“…202 Background: Treatment options that are durably effective for patients with metastatic (m) castration-resistant prostate cancer (CRPC) remain limited…”
Get full text

Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor) by Palumbo, Antonio, Dimopoulos, Meletios A., Reece, Donna Ellen, Sonneveld, Pieter, Spencer, Andrew, Chanan-Khan, Asher Alban Akmal, Goldschmidt, Hartmut, Yeh, Howard, Schecter, Jordan Mark, Qin, Xiang, Amin, Himal, Guckert, Mary E., Ahmadi, Tahamtan, Orlowski, Robert Z.

“…Abstract only…”
Get full text

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503) by Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C., Lassen, Ulrik, Laubach, Jacob P., Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A Kate, Guckert, Mary E, Yeh, Howard, Ahmadi, Tahamtan, Lokhorst, Henk M., Richardson, Paul G.

“…▪ Introduction: Daratumumab (DARA) is a human anti-CD38 IgG1κ monoclonal antibody that showed synergistic anti-tumor activity in combination with lenalidomide…”
Get full text

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma by Plesner, Torben, Arkenau, Hendrik-Tobias, Lokhorst, Henk M., Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C., Lassen, Ulrik, Laubach, Jacob P., Ahmadi, Tahamtan, Yeh, Howard, Guckert, Mary E, Feng, Huaibao, Brun, Nikolai Constantin, Lisby, Steen, Basse, Linda, Palumbo, Antonio, Richardson, Paul G.

“…Background: Daratumumab (DARA) (HuMax™-CD38), a human IgG1κ monoclonal antibody effectively mediates destruction of CD38-expressing malignant plasma cells. In…”
Get full text

An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM) by Hauschild, Axel, Grob, Jean Jacques, Demidov, Lev V., Jouary, Thomas, Gutzmer, Ralf, Millward, Michael, Rutkowski, Piotr, Blank, Christian U., Miller, Wilson H., Kaempgen, Eckhart, Martin-Algarra, Salvador, Karaszewska, Boguslawa, Mauch, Cornelia, Chiarion-Sileni, Vanna, Mirakhur, Beloo, Guckert, Mary E., Swann, R. Suzanne, Haney, Patricia, Goodman, Vicki L., Chapman, Paul B.

“…Abstract only 9013 Background: Dabrafenib is a selective BRAF inhibitor with demonstrated efficacy in BRAF V600E-positive mutation in MM. The primary analysis…”
Get full text

Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF V600E -mutated melanoma by Hauschild, Axel, Grob, Jean Jacques, Demidov, Lev V., Jouary, Thomas, Gutzmer, Ralf, Millward, Michael, Rutkowski, Piotr, Blank, Christian U., Mirakhur, Beloo, Guckert, Mary E., Swann, R. Suzanne, Haney, Patricia, Martin, Anne-Marie, Ouellet, Danielle, Grotzinger, Kelly, Goodman, Vicki L., Chapman, Paul B.

“…Abstract only LBA8500^ Background: Dabrafenib, a selective BRAF inhibitor, has shown activity with a manageable safety profile in phase I/II studies in…”
Get full text

Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF V600E -mutated melanoma by Hauschild, Axel, Grob, Jean Jacques, Demidov, Lev V., Jouary, Thomas, Gutzmer, Ralf, Millward, Michael, Rutkowski, Piotr, Blank, Christian U., Mirakhur, Beloo, Guckert, Mary E., Swann, R. Suzanne, Haney, Patricia, Martin, Anne-Marie, Ouellet, Danielle, Grotzinger, Kelly, Goodman, Vicki L., Chapman, Paul B.

“…Abstract only LBA8500^ The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the…”
Get full text

BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets) by Kirkwood, John M., Long, Georgina V., Trefzer, Uwe, Davies, Michael A., Ascierto, Paolo Antonio, Chapman, Paul B., Puzanov, Igor, Hauschild, Axel, Robert, Caroline, Kefford, Richard, Goodman, Vicki L., Switzky, Julie C., Swann, R. Suzanne, Martin, Anne-Marie, Guckert, Mary E., Streit, Michael R. W., Schadendorf, Dirk

“…Abstract only 8501 Background: Melanoma brain mets carry a poor prognosis (median survival ≤4 months), for which more effective therapies are needed…”
Get full text

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlledtrial by HAUSCHILD, Axel, GROB, Jean-Jacques, MARTIN-ALGARRA, Salvador, KARASZEWSKA, Bogusiawa, MAUCH, Cornelia, CHIARION-SILENI, Vanna, MARTIN, Anne-Marie, SWANN, Suzanne, HANEY, Patricia, MIRAKHUR, Beloo, GUCKERT, Mary E, GOODMAN, Vicki, DEMIDOV, Lev V, CHAPMAN, Paul B, JOUARY, Thomas, GUTZMER, Ralf, MILLWARD, Michael, RUTKOWSKI, Piotr, BLANK, Christian U, MILLER, Wilson H, KAEMPGEN, Eckhart

Get full text